PURPOSE: Previous studies suggest that some common medications alter prostate-specific antigen (PSA) levels. It remains unclear whether these reported medication effects are due to clinicodemographic factors or concurrent use of other medications. We investigated the impact of individual and combinations of common medications on PSA in a large cross-sectional study of the United States population. PATIENTS AND METHODS: The study included men > or = 40 years old without prostate cancer from the 2003 to 2004 and 2005 to 2006 cycles of the National Health and Nutrition Examination Survey (NHANES). Men with recent prostate manipulation, prostatitis, and those on hormone therapy were excluded. Weighted multivariate linear regression was performed on log-transformed total PSA to determine the effect of the 10 most commonly prescribed medication classes, adjusting for potential confounders including demographics, clinical characteristics, physical examination, laboratory studies, and duration of medication use. RESULTS: In total, 1,864 men met inclusion criteria. Nonsteroidal anti-inflammatory drug (NSAID; P = .03), statin (P = .01), and thiazide diuretic (P = .025) intake was inversely related to PSA levels. Five years of NSAID, statin, and thiazide diuretic use was associated with PSA levels lower by 6%, 13%, and 26%, respectively. The combination of statins and thiazide diuretics showed the greatest reduction in PSA levels: 36% after 5 years. Concurrent calcium channel blocker use minimizes or negates the inverse relationship of statin use and PSA level. CONCLUSION: We found that men using NSAIDs, statins, and thiazide diuretics have reduced PSA levels by clinically relevant amounts. The impact of regularly consuming these common medications on prostate cancer screening is unknown.
PURPOSE: Previous studies suggest that some common medications alter prostate-specific antigen (PSA) levels. It remains unclear whether these reported medication effects are due to clinicodemographic factors or concurrent use of other medications. We investigated the impact of individual and combinations of common medications on PSA in a large cross-sectional study of the United States population. PATIENTS AND METHODS: The study included men > or = 40 years old without prostate cancer from the 2003 to 2004 and 2005 to 2006 cycles of the National Health and Nutrition Examination Survey (NHANES). Men with recent prostate manipulation, prostatitis, and those on hormone therapy were excluded. Weighted multivariate linear regression was performed on log-transformed total PSA to determine the effect of the 10 most commonly prescribed medication classes, adjusting for potential confounders including demographics, clinical characteristics, physical examination, laboratory studies, and duration of medication use. RESULTS: In total, 1,864 men met inclusion criteria. Nonsteroidal anti-inflammatory drug (NSAID; P = .03), statin (P = .01), and thiazide diuretic (P = .025) intake was inversely related to PSA levels. Five years of NSAID, statin, and thiazide diuretic use was associated with PSA levels lower by 6%, 13%, and 26%, respectively. The combination of statins and thiazide diuretics showed the greatest reduction in PSA levels: 36% after 5 years. Concurrent calcium channel blocker use minimizes or negates the inverse relationship of statin use and PSA level. CONCLUSION: We found that men using NSAIDs, statins, and thiazide diuretics have reduced PSA levels by clinically relevant amounts. The impact of regularly consuming these common medications on prostate cancer screening is unknown.
Authors: Matthijs R Graaf; Annette B Beiderbeck; Antoine C G Egberts; Dick J Richel; Henk-Jan Guchelaar Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: S Zha; W R Gage; J Sauvageot; E A Saria; M J Putzi; C M Ewing; D A Faith; W G Nelson; A M De Marzo; W B Isaacs Journal: Cancer Res Date: 2001-12-15 Impact factor: 12.701
Authors: Ian M Thompson; Chen Chi; Donna Pauler Ankerst; Phyllis J Goodman; Catherine M Tangen; Scott M Lippman; M Scott Lucia; Howard L Parnes; Charles A Coltman Journal: J Natl Cancer Inst Date: 2006-08-16 Impact factor: 13.506
Authors: M P Ares; M I Pörn-Ares; J Thyberg; L Juntti-Berggren; P O Berggren; U Diczfalusy; B Kallin; I Björkhem; S Orrenius; J Nilsson Journal: J Lipid Res Date: 1997-10 Impact factor: 5.922
Authors: S Wassertheil-Smoller; M D Blaufox; A Oberman; B R Davis; C Swencionis; M O Knerr; C M Hawkins; H G Langford Journal: Ann Intern Med Date: 1991-04-15 Impact factor: 25.391
Authors: Dima M Qato; G Caleb Alexander; Rena M Conti; Michael Johnson; Phil Schumm; Stacy Tessler Lindau Journal: JAMA Date: 2008-12-24 Impact factor: 56.272
Authors: Jorge D Escandriolo Nackauzi; Raúl H Colla; Graciela R Ravazzani; María I Gaido; Patricia Bertolotto; Adriana B Actis Journal: Med Oncol Date: 2011-04-12 Impact factor: 3.064
Authors: Emma H Allott; Ilona Csizmadi; Lauren E Howard; Roberto L Muller; Daniel M Moreira; Gerald L Andriole; Claus G Roehrborn; Stephen J Freedland Journal: BJU Int Date: 2019-09-27 Impact factor: 5.588
Authors: Emma H Allott; Lauren E Howard; Adriana C Vidal; Daniel M Moreira; Ramiro Castro-Santamaria; Gerald L Andriole; Stephen J Freedland Journal: Cancer Prev Res (Phila) Date: 2017-05-09
Authors: Mahmoud A Alfaqih; Emma H Allott; Robert J Hamilton; Michael R Freeman; Stephen J Freedland Journal: Nat Rev Urol Date: 2016-10-25 Impact factor: 14.432
Authors: Cheryl Jacobs Smith; Tiffany H Dorsey; Wei Tang; Symone V Jordan; Christopher A Loffredo; Stefan Ambs Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-03-14 Impact factor: 4.254
Authors: Michael A Poch; Diana Mehedint; Dawn J Green; Rochelle Payne-Ondracek; Elizabeth T H Fontham; Jeannette T Bensen; Kristopher Attwood; Gregory E Wilding; Khurshid A Guru; Willie Underwood; James L Mohler; Hannelore V Heemers Journal: Prostate Date: 2012-12-31 Impact factor: 4.104